Navigation Links
PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting
Date:2/24/2009

ANNAPOLIS, Md., Feb. 24 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Alternext US: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that results from a Phase II study of SparVax(TM) and pharmacokinetic (PK) data for Valortim(R) were presented at the 7th Annual ASM Biodefense and Emerging Diseases Research Meeting, being held in Baltimore, MD, February 22-25, 2009.

David P. Wright, President and Chief Executive Officer of PharmAthene commented, "The ASM conference is among the leading industry meetings of the year for biodefense and we are pleased to be able to showcase advancements in each of our SparVax(TM) and Valortim(R) programs to key policy makers at this important meeting."

"PharmAthene has received tremendous support from a variety of government funding partners, including, the Department of Defense, the Department of Health and Human Services, and the National Institute of Allergy and Infectious Diseases. This unprecedented collaborative effort will help to ensure the development of urgently needed medical countermeasures to meet the biosecurity needs of our Nation and Allies."

SparVax(TM) is a novel second generation recombinant protective antigen (rPA) anthrax vaccine that is being developed for pre and post exposure protection against anthrax infection. Valortim(R), in co-development with Medarex, Inc. (Nasdaq: MEDX), is a fully human monoclonal antibody designed to protect against and treat inhalational anthrax, the most lethal form of illness in humans caused by anthrax.

SparVax(TM) Phase II Clinical Data

Results from a Phase II clinical trial of SparVax(TM) were presented during a poster session by Dr. Matthew Duchars, Chief Scientific Officer for PharmAthene. The Phase II trial was designed t
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel
2. Pharmathene Reports Third Quarter 2008 Financial and Operational Results
3. PharmAthene to Host Third Quarter 2008 Conference Call and Webcast on Thursday, November 13, 2008
4. PharmAthene to Present on Wednesday, November 12th at the 10th Annual Rodman & Renshaw Healthcare Conference
5. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
6. PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
7. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
8. PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008
9. PharmAthene to Present at the UBS Global Life Sciences Conference on Thursday September 25, 2008
10. PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
11. PharmAthene Reports Second Quarter 2008 Financial and Operational Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...e New York investment bank KTA Capital,s client Ne...U$6.7 mil convertible note private placement with ...nt was arranged by KTA Capital as Neuren,s exclusi... New York (PRWEB) November 23, 2009 -- The... LLC ("KTA Capital") has announced that ...
(Date:11/24/2009)...vember24/PRNewswire-FirstCall/--deCODE,genetics,In...ticefrom,theNasdaqStockMarketthattradinginthecompa...andaForm25-NSEwillbefiledwiththe,SecuritiesandExch...fromlistingonNasdaq,unlessthecompanyfilesanappealt...sfiledsuchanappeal,which,willstaythesuspensionandd...
(Date:11/24/2009)...vember24/PRNewswire-FirstCall/--deCODE,genetics,In...ts,"firstday"motionsbytheU.S.BankruptcyCourtforthe...stweekfiledavoluntarypetitionfor,reliefunderChapte...cyCourt. , TheordersissuedbytheBankruptcyCour...ingtheChapter11proceedings.Inparticular,the,compan...
(Date:11/24/2009)...wswire-Asia/--ShanghaiBiolaxyannouncedthe,ChineseS...e,investigationalnewdrugapplication(IND)foritsoral...tiontotreatdiabetes.ThisIND,approvalallowsBiolaxyt...tesisadisordercharacteristicofhighbloodglucoseandp...ltinseveremicro-and,macro-vasculardiseases,lossofv...
Breaking Biology Technology:KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Biolaxy Secures IND Approval for Oral Insulin 2
... Nominees on the Blue Proxy Card Today , , RiskMe... SAN DIEGO, May 15 Amylin Pharmaceuticals, Inc. (...ent in response to a report issued by RiskMetrics ...) regarding Amylin,s Annual Meeting of Stockholder... for shareholders to note that RiskMetrics split i...
..., Inc. (NYSE Amex: ILI ) announced today that it... on Wednesday, May 20, 2009, at 2:40 p.m. EDT in R...GA. Lewis H. Bender, Chief Executive Officer, will...clude the Company,s business model, available gene...sting and personalized medicine offer a significan...
... Inc. announced today that it has acquired exclu... Children,s Hospital Boston and Massachusetts Gene...ompositions and methods for supporting hematopoiet...eloped by Leonard Zon, M.D., director of the Stem ...cientific founder of Fate Therapeutics, expand the...
Other Biology Technology:Amylin Comments on RiskMetrics Report 2Amylin Comments on RiskMetrics Report 3Amylin Comments on RiskMetrics Report 4Amylin Comments on RiskMetrics Report 5Interleukin Genetics to Present at the 2009 BIO Business Forum 2Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Children's Hospital Boston and Massachusetts General Hospital 2Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Children's Hospital Boston and Massachusetts General Hospital 3
(Date:11/25/2009)...sts at the California Institute of Technology (Cal...on-like behavior in the fruit fly, Drosophila mel...ant to the relationship between the neurotransmitt...sorder (ADHD), are described in the December issue...in contains only about 20,000 neurons and has long...
(Date:11/25/2009)...on,t have easy lives. In addition to mammalian imm...al enemies called bacteriophages, viruses that kil...Still, bacteria and another class of microorganism...ronments such as deep-sea volcanic vents) manage j...uilt-in defense system that helps protect them fro...
(Date:11/25/2009)...ad of the Cell Death Research Laboratory in the Un...n awarded the prestigious Johnson & Johnson Focuse...se of brain cell damage in Parkinson,s disease. Th...in support of innovation and excellence in science...earlier this month at an event at the Hyatt Regenc...
Breaking Biology News(10 mins):Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 2Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 3Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 4Researchers discover biological basis of 'bacterial immune system' 2Researchers discover biological basis of 'bacterial immune system' 3Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2Spherix Announces the Closing of 246 3 Million Registered Direct Offering 14924 1Spherix Announces the Closing of 246 3 Million Registered Direct Offering 14924 2Spherix Announces the Closing of 246 3 Million Registered Direct Offering 14924 3The Deal Names Abbott Top Dealmaker for Second Consecutive Year 6418 1The Deal Names Abbott Top Dealmaker for Second Consecutive Year 6418 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 6418 3AUDIO from Medialink and Ortho McNeil Janssen Pharmaceuticals Inc 3A Getting Ready for Cold and Flu Season 6416 1
...led by Johns Hopkins suggests that the rate of HIV...ica that HIV dementia along with Alzheimer’s disea... common forms of dementia in the world. , In the f...t using rigorous neurological and neuropsychologic...resentative group of HIV-positive patients in Ugan...
... oceans mean that bay scallops and other shellfish... an article in the March 30 issue of the journal S...o the same fate. , A team of Canadian and America...ogist Ransom Myers at Dalhousie University, has fo... such as the bull, great white, dusky, and hammerh...
... the May/June 2007 issue of the journal Ground Wat...s and, consequentially, ground water due to incomp... stream or by disposal of unused medications in th... study investigated the occurrence of pharmaceutic...ks located in sand and gravel deposits in Missoula...
Other Biology News:HIV dementia alarmingly high in Africa 2Overfishing large sharks impacts entire marine ecosystem, shrinks shellfish supply 2Overfishing large sharks impacts entire marine ecosystem, shrinks shellfish supply 3Overfishing large sharks impacts entire marine ecosystem, shrinks shellfish supply 4
Corning Cryo Vial Rack, PC, Holds 30 Self-Standing Vials, Non-Sterile from Sigma-Aldrich
...ster GX-1000 3-D Shaker , ,Product Information ,...Twister GX-1000 is extremely efficient, yet gentle...ell as staining gels, hybridization and other appl... across a broad range. A nonslip rubber mat and el...
SlideHyb Glass Array Hybridization Buffer #1 from Ambion
...emical Purity is >95%NEN Radiolabeled Ligands\n\nR...the continual availability of new radiolabeled lig...erkinElmer offers a wide range of products and ser...cluding over 400 state-of-the-art radioligands. If...
Biology Products: